HIGHLIGHTS
==========

\- Urinary NGF levels were higher at baseline in patients who did not experience recurrence than in those who did after antimuscarinic treatment.

\- In patients who did not experience recurrence, urinary NGF/Cr decreased at the end of treatment compared to baseline, and this reduction was maintained at 12 weeks after the end of treatment.

INTRODUCTION
============

Overactive bladder (OAB) is a complex clinical syndrome of urinary urgency, usually accompanied by nocturia and frequency with or without urgency urinary incontinence \[[@b1-inj-1732794-397]\]. Its overall prevalence in males and females older than 40 years is 16.6% in Europe \[[@b2-inj-1732794-397]\]. Additionally, its prevalence tends to increase with age \[[@b3-inj-1732794-397],[@b4-inj-1732794-397]\]. The pathogenesis of OAB may be multifactorial and has yet to be fully clarified \[[@b5-inj-1732794-397]\]. The diagnosis of OAB and the evaluation of the efficacy of OAB treatments are usually made based on a careful history and various tools, including voiding diaries and symptom questionnaires. Urodynamic studies can be used in selected cases.

Antimuscarinic treatment for OAB is usually effective, but the efficacy of treatment varies based on the severity of symptoms and pathophysiology, and 35% of patients experience recurrence after discontinuing treatment \[[@b6-inj-1732794-397]\]. It is difficult to evaluate the efficacy of antimuscarinic treatment and to determine the adequate duration of treatment. In addition, concerns about the reliability of correlations between symptoms and urodynamic findings have been reported \[[@b7-inj-1732794-397],[@b8-inj-1732794-397]\]. Therefore, a new, reliable, and accurate test for evaluating OAB patients and relevant therapeutic outcomes is needed \[[@b9-inj-1732794-397]\].

Nerve growth factor (NGF) is a neurotrophic factor that induces growth, differentiation, and survival of specific target neurons. NGF is released by smooth muscle and urothelium as a chemical mediator in the bladder \[[@b10-inj-1732794-397]\]. In an animal model, NGF triggered bladder hypersensitivity through the sensitization of afferent nerve pathways \[[@b11-inj-1732794-397]\]. Urinary NGF levels were found to be elevated in OAB patients in previous studies, and it has been proposed that urinary NGF could be a biomarker of OAB \[[@b12-inj-1732794-397]-[@b14-inj-1732794-397]\]. However, studies that investigated urinary NGF as a way of evaluating the efficacy of OAB treatment have demonstrated inconsistent results \[[@b12-inj-1732794-397],[@b15-inj-1732794-397],[@b16-inj-1732794-397]\]. Thus, we investigated changes in urinary NGF levels in subjects with OAB following antimuscarinic treatment in order to predict treatment efficacy and recurrence.

MATERIALS AND METHODS
=====================

Subjects
--------

This study was approved by the Institutional Review Board of Samsung Medical Center (approval number: 2010-05-106) and was registered at <http://clinicaltrials.gov> (ClinicalTrials.gov ID: NCT01499069). Written informed consent was obtained from all subjects. We enrolled 189 subjects older than 18 years who visited our outpatient clinic between February 2010 and February 2015 and who had a symptom duration of ≥3 months, with ≥8 micturition events per 24 hours and ≥2 urgency episodes per 24 hours reported in 3-day voiding diaries.

Subjects were excluded if they had stress incontinence, hepatic or renal disease, any condition that is a contraindication for anticholinergic treatment, symptomatic acute or recurrent urinary tract infection, interstitial cystitis, uninvestigated hematuria or hematuria secondary to malignant disease, bladder outlet obstruction, pelvic organ prolapse, bladder cancer or prostate cancer, chronic constipation, treatment with potent CYP3A4 inhibitors, or treatment with any anticholinergic drugs or any drug for OAB within the 14 days preceding randomization, or if they expected to initiate treatment with such a drug during the study. Subjects also were excluded if they used an unstable dosage of any drug with anticholinergic side effects or expected to start such treatment during the study, if they were pregnant or nursing, or if they had an indwelling catheter or practiced intermittent self-catheterization. We also excluded sexually active females with childbearing potential who were not using reliable contraception, patients with a history of electrostimulation or bladder training within the 14 days before randomization, those who expected to start such treatment during the study, and patients who used any investigational drug within 2 months preceding the start of the study. Patients were also excluded if they had any other condition that, in the opinion of the investigator, made them unsuitable for inclusion.

Study Design
------------

The study design is summarized in [Fig. 1](#f1-inj-1732794-397){ref-type="fig"}. All subjects with OAB received antimuscarinic treatment (4 mg of fesoterodine once daily) and visited our outpatient clinic 4 and 12 weeks (and 24 weeks for patients who completed treatment at 24 weeks) after beginning treatment, as well as 4 and 12 weeks after completing treatment. A 3-day voiding diary, urine samples for evaluating NGF and urinary creatinine (Cr), the Overactive Bladder Questionnaire Short Form (OAB-q SF) symptom bother and health-related quality of life (HRQL) scores, and the overactive bladder symptom score (OABSS) were collected. Urinary levels of NGF were corrected using urinary Cr levels.

Treatment was discontinued at 12 weeks if there was a decrease in micturition events of \>2 times per 24 hours, a greater than a 50% decrease in urgency episodes, and if subjects expressed satisfaction on the questionnaire about patients' perceptions of treatment benefits. If subjects did not satisfy these criteria, they received anticholinergics for 12 more weeks and were reevaluated with the same criteria. For subjects who did not meet the criteria at 24 weeks, antimuscarinic treatment was maintained. After completing treatment, subjects who were not satisfied according to the questionnaire on patients' perceptions of treatment benefits and those who had an increase in micturition events of \>2 times per 24 hours and/or a greater than 50% increase in urgency episodes were classified as experiencing recurrence.

The baseline characteristics of responders and nonresponders were analyzed according to age, sex, body mass index, OAB subgroup, OAB pathogenesis, urinary frequency, urinary urgency, OAB-q SF symptom bother and HRQL, OABSS, and urinary NGF/Cr. Baseline characteristics of patients who did or did not experience recurrence were analyzed in the same manner. Multiple logistic regression analysis was performed in responders and nonresponders and in those who did or did not experience recurrence to identify predictive factors of response to antimuscarinic treatment and recurrence, respectively. Urinary NGF levels after beginning anticholinergic treatment were compared in responders and nonresponders. Urinary NGF levels were also compared after the completion of antimuscarinic treatment in patients who did or did not experience recurrence. A subanalysis was performed according to sex.

Urinary NGF and Cr Measurements
-------------------------------

Voided urine from all subjects was collected at enrollment, at 4 and 12 weeks (and 24 weeks for patients who discontinued treatment at 24 weeks) after the beginning of antimuscarinic treatment, and at 4 and 12 weeks after the completion of treatment. Urine samples were kept on ice and then centrifuged at 3,000 rpm at 4°C for 10 minutes. The supernatant was separated into aliquots in 1.5-mL tubes and preserved at -80°C. Urinary Cr was measured in 3-mL urine aliquots.

The urinary NGF concentration was measured using the NGF Emax ImmunoAssay System (Promega Corp., Madison, WI, USA). The wells of 96-well plates were coated with 10 μL of anti-NGF polyclonal antibody diluted in 10 μL of carbonate coating buffer (pH, 9.7) and incubated at 4°C overnight after sealing the wells. Then, the wells were washed 3 times with Tris buffered saline with Tween-20 washing buffer (20 mM TrisHCl, 150 mM NaCl, and 0.05% Tween 20). Each well was incubated with 200 μL of 1×buffer and sample buffer at room temperature for 1 hour to prevent nonspecific reactions. An NGF standard (prepared from the 1 μg/mL stock solution) and 100 μL of urine were added to the wells. The wells were washed 5 times after incubation for 6 hours, and 100 μL of secondary antibody (2.5 μL of anti-NGF monoclonal antibody that was diluted in 10 mL of 1×block and sample buffer) was added to each well. The plates were then incubated at 4°C overnight. Subsequently, 100 μL of anti-rat immunoglobulin G horseradish peroxidase conjugate was added to each well after washing 5 times with TBST washing buffer, and the wells were incubated at room temperature for 2.5 hours. The wells were again washed 5 times with TBST washing buffer. Then, they were incubated with 100 μL of tetramethylbenzidine (dissolved in a proprietary buffer) substrate solution at room temperature for 10 minutes. For termination of the reactions, 100 μL of 1N hydrochloric acid was added. The amount of NGF was determined by the VersaMax ELISA Microplate Reader (Molecular Devices, Inc., Sunnyvale, CA, USA) at 450 nm.

Statistical Analysis
--------------------

Data are expressed as mean±standard error of the mean. The Mann-Whitney U-test was used for between-group comparisons. The chi-square test was used for categorical data. Multivariate logistic regression analysis was used to predict response to anticholinergic treatment and recurrence. All variables with a P-value \<0.20 in the univariate analysis were incorporated into the multivariate analyses. The Wilcoxon signed-rank test with the Bonferroni correction was used for intragroup comparisons. A receiver operating characteristic (ROC) curve was used to analyze the feasibility of NGF as a biomarker. Values of P\<0.05 were considered to indicate statistical significance, and all statistical tests were 2-sided. All statistical analyses were performed using IBM SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA).

RESULTS
=======

The flow diagram of the progress of all subjects is presented in [Fig. 2](#f2-inj-1732794-397){ref-type="fig"}. Among the 189 enrolled OAB subjects, 92 completed the study. Their mean age was 55.0±1.5 years. The percentages of female and male subjects were 78.3% (72 of 92) and 21.7% (20 of 92), respectively. The mean number of micturition events per 24 hours was 11.9±0.3, and the mean number of urgency episodes per 24 hours was 8.4±0.5. The mean OAB-q SF symptom bother score was 20.9±0.6, the mean OAB-q SF HRQL score was 42.6±1.2, and the mean OABSS was 9.0±0.2.

The baseline characteristics of responders (n=62) and nonresponders (n =30) are summarized in [Table 1](#t1-inj-1732794-397){ref-type="table"}. No variables except OAB-q SF HRQL score were significantly different between the 2 groups. No significant difference was found in the subanalysis according to sex. There were no significant predictors of response to antimuscarinic treatment in the logistic regression analysis ([Table 2](#t2-inj-1732794-397){ref-type="table"}). The baseline characteristics of the no recurrence and recurrence groups in the patients who responded to medical treatment with antimuscarinics are summarized in [Table 3](#t3-inj-1732794-397){ref-type="table"}. The baseline urinary level of NGF/Cr was higher in those who did not experience recurrence than in those who did (P=0.047). This finding was also noted in the subanalysis of female and male subjects. In the logistic regression analysis, change in the urinary level of NGF/Cr (evaluated by subtracting the urinary level of NGF/Cr at baseline from the urinary level of NGF/Cr at the completion of treatment) was a significant predictor of recurrence regardless of sex ([Table 4](#t4-inj-1732794-397){ref-type="table"}).

Among responders (n =62), the urinary level of NGF/Cr tended to decrease, but there was no significant change after beginning antimuscarinic treatment ([Fig. 3](#f3-inj-1732794-397){ref-type="fig"}). Among those who did not experience recurrence (n =29), the urinary level of NGF/Cr after treatment decreased compared to baseline (P=0.024) and remained significantly decreased 12 weeks after the end of treatment (P=0.002). The recurrence group (n=33) did not show any significant change in the urinary level of NGF/Cr ([Fig. 4](#f4-inj-1732794-397){ref-type="fig"}). These results were also found in the subanalysis according to sex.

In the ROC curve analysis of urinary NGF/Cr among responders to antimuscarinic treatment, change in the urinary level of NGF/Cr (evaluated by subtracting the urinary level of NGF/Cr at baseline from the urinary level of NGF/Cr at the completion of treatment) discriminated the no recurrence group from the recurrence group in the subjects overall, in female subjects, and in male subjects (area under the curve \[AUC\] =0.65; 95% confidence interval \[CI\], 0.52--0.80; P = 0.043; AUC=0.66; 95% CI, 0.55--0.80; P=0.037; AUC=0.63; 95% CI, 0.52--0.77; P=0.045, respectively).

DISCUSSION
==========

In this study, we investigated the potential of urinary NGF as a biomarker for prediction of the efficacy of antimuscarinic treatment and recurrence. In previous studies, urinary NGF/Cr levels significantly decreased after antimuscarinic treatment \[[@b12-inj-1732794-397]\], and were significantly reduced in responders in other studies \[[@b13-inj-1732794-397],[@b15-inj-1732794-397]\]. However, we observed different results. The present study demonstrated that urinary NGF/Cr levels tended to decrease in responders, including both recurrent and nonrecurrent patients, but this change was not statistically significant. Patients who did not experience recurrence showed a significant decrease in urinary NGF/Cr levels after treatment. Urinary NGF/Cr appeared to decrease only in those who did not experience recurrence. This finding is the main strength of our study, suggesting that medication cessation should be considered only in those who maintain lowered urinary NGF/Cr levels compared to baseline by the end of treatment. Interestingly, in the recurrence group, the urinary NGF/Cr level showed a tendency to increase after treatment, despite the response to antimuscarinics. This result implies that an unknown mechanism of anticholinergics may have been present in the no recurrence group. The mechanism through which the urinary level of NGF increases in OAB patients is not yet established. Stretching of the bladder smooth muscle cells increased the expression of messenger RNA for NGF and stimulated the secretion of NGF in vitro \[[@b17-inj-1732794-397]\]. A decreased urinary level of NGF after antimuscarinic treatment might be related to the suppression of bladder smooth muscle as a result of OAB symptom improvement \[[@b15-inj-1732794-397]\]. Further studies to confirm these results, as well as research into the precise mechanism, are required.

The finding that a significant decrease in urinary NGF/Cr is predictive that no recurrence will take place after treatment could help physicians to make the decision to stop antimuscarinic treatment. In the present study, a change in the urinary levels of NGF/Cr was revealed as a potential test for identifying patients who will not experience recurrence (AUC=0.65; 95% CI, 0.52--0.80; P=0.043). Although the discrimination power is not particularly high, this finding is of value considering that there is currently no definite way to decide when to stop antimuscarinic treatment in responders.

Increased urinary NGF levels have been reported in various lower urinary tract dysfunctions. Urinary levels of NGF/Cr were elevated in patients with interstitial cystitis/bladder pain syndrome \[[@b18-inj-1732794-397]\]. Elevated urinary NGF levels were not observed in patients with urodynamic stress urinary incontinence \[[@b19-inj-1732794-397]\], but increased urinary NGF levels were reported in a rat model of stress urinary incontinence \[[@b20-inj-1732794-397]\]. Bladder outlet obstruction stimulated an increase in urinary NGF \[[@b21-inj-1732794-397]\]. Elevated urinary NGF levels have also been found in other conditions, including stones, urinary tract infections, and bladder tumors \[[@b18-inj-1732794-397],[@b22-inj-1732794-397]\]. Additionally, a relatively wide variation in urinary NGF was found in the present study. The fact that duplicate urinary samples were not analyzed when measuring urinary NGF and Cr to minimize the variation is a limitation of this study. Although NGF may have some limitations as a biomarker of OAB, we believe that urinary NGF levels may be useful for evaluating treatment outcomes in clinically diagnosed OAB patients.

Along with NGF, other neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) have also been investigated as biomarkers for OAB. BDNF is expressed in the urothelium and exerts an influence through TrkB receptors \[[@b23-inj-1732794-397]\]. The nonpeptidergic subpopulation is regulated by GDNF, which binds to GDNF family receptor α1 \[[@b24-inj-1732794-397],[@b25-inj-1732794-397]\]. Urinary BDNF levels were significantly higher in OAB patients than in healthy controls and were normalized after the treatment of OAB, while urinary GDNF levels did not significantly differ between those 2 groups \[[@b12-inj-1732794-397],[@b23-inj-1732794-397],[@b26-inj-1732794-397]\]. These data suggest that BDNF is also an important element in the pathogenesis of OAB. Further studies of urinary neurotrophins, including NGF and BDNF, are required for understanding the pathogenesis and improving the treatment of OAB.

Of note, the Promega (Madison, WI, USA) discontinued production of the NGF Emax ImmunoAssay System on March 15, 2014, during the study period. However, the measurement of urinary NGF was not interrupted in this study, as our stock was sufficient. Thus, measurements of NGF were performed consistently with the same kit.

Recently, questions about the suitability of the Promega assay for the detection of NGF in urine have been raised \[[@b27-inj-1732794-397]\]. Researchers reported cross-reactions of the assay with urinary compounds, which could be another limitation of the present study. Although this is an important concern about the validity of the Promega assay that should be clarified, we believe that our serial data of urinary NGF/Cr in each patient nonetheless show the potential of urinary NGF as a biomarker of treatment outcomes. Future studies to confirm our findings using other assays are needed.

We report the novel outcome of urinary NGF being useful as a potential biomarker for predicting the outcome of antimuscarinic treatment in OAB patients in this study. To the best of our knowledge, the finding of a decrease in urinary NGF/Cr only among patients who did not experience recurrence has not been reported in previous studies. This may provide useful information regarding the decision of when to stop antimuscarinic treatment in responders.

In conclusion, urinary NGF/Cr levels tended to decrease after antimuscarinic treatment, but this was not significant. Those who did not experience recurrence had higher baseline urinary NGF/Cr levels than the recurrence group. In those who did not experience recurrence, urinary NGF/Cr decreased at the completion of treatment compared to baseline, and this was maintained for 12 weeks after completion of treatment.

These data suggest that urinary NGF can serve as a potential biomarker for predicting treatment outcomes in OAB patients. This may provide useful information regarding the decision of when to stop antimuscarinic treatment in responders.

**Grant/Fund Support**

The research was supported by a Samsung Biomedical Research Institute grant, \#SBRI C-B0-227, and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C3229).

**Research Ethics**

This study was approved by the Institutional Review Board of Samsung Medical Center (approval number: 2010-05-106) and was registered at <http://clinicaltrials.gov> (ClinicalTrials.gov ID: NCT01499069). Written informed consent was obtained from all subjects.

**Conflict of Interest**

No potential conflict of interest relevant to this article was reported.

![Study design incorporating OAB subjects. ^a)^Cases of treatment discontinuation at 24 weeks; ^b)^Patients who discontinued antimuscarinic treatment at 12 or 24 weeks. OAB, overactive bladder; Tx., treatment.](inj-1732794-397f1){#f1-inj-1732794-397}

![The flow diagram of the progress of all subjects. OAB, overactive bladder.](inj-1732794-397f2){#f2-inj-1732794-397}
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###### 

Baseline characteristics of responders and nonresponders in patients who underwent medical treatment with antimuscarinics

  Characteristic           Overall      Female       Male                                                                                                       
  ------------------------ ------------ ------------ ------------ ------- ------------ ------------ ------------ ------- ------------ ------------ ------------ -------
  Age                      55.0 ± 1.5   54.9 ± 1.6   55.2 ± 3.1   0.918   57.3 ± 1.4   55.4 ± 1.6   61.1 ± 2.7   0.061   46.8 ± 4.1   50.2 ± 4.6   41.6 ± 3.8   0.092
  Sex                                                             0.778                                                                                         
   Male                    20 (21.7)    14 (22.6)    6 (20.0)                                                                                                   
   Female                  72 (78.3)    48 (77.4)    24 (80.0)                                                                                                  
  BMI (kg/m^2^)            23.3 ± 0.2   23.6 ± 2.7   22.6 ± 3.0   0.168   23.5 ± 0.3   23.9 ± 0.4   22.6 ± 0.6   0.077   22.7 ± 0.4   22.7 ± 0.5   22.7 ± 1.1   0.974
  OAB subgroup                                                    0.959                                          0.381                                          0.085
   OAB-dry                 61 (66.3)    41 (66.1)    20 (66.7)            47 (65.3)    33 (68.8)    15 (62.5)            14 (70.0)    8 (57.1)     5 (83.3)     
   OAB-wet                 31 (33.7)    21 (33.9)    10 (33.3)            25 (34.7)    15 (31.2)    9 (37.5)             6 (30.0)     6 (42.9)     1 (16.7)     
  OAB pathogenesis                                                0.687                                          0.791                                          0.219
  Idiopathic               81 (88.0)    54 (87.1)    27 (90.0)            65 (90.3)    43 (89.6)    22 (91.7)            16 (80.0)    11 (78.6)    5 (83.3)     
  Neurogenic               11 (12.0)    8 (12.9)     3 (10.0)             7 (9.7)      5 (10.4)     2 (8.3)              4 (20.0)     3 (21.4)     1 (16.7)     
  Micturitions/24 hr       11.9 ± 0.3   11.7 ± 0.4   12.6 ± 4.5   0.611   11.9 ± 0.4   11.6 ± 0.5   12.5 ± 0.9   0.33    12.2 ± 0.8   12.0 ± 0.8   12.7 ± 2.3   0.776
  Urgency episodes/24 hr   8.4 ± 0.5    7.7 ± 0.5    9.8 ± 6.6    0.202   8.0 ± 0.5    7.5 ± 0.6    9.1 ± 0.9    0.131   9.8 ± 1.5    8.7 ± 0.9    12.3 ± 4.9   0.508
  OAB-q SF                                                                                                                                                      
   Symptom bother          20.9 ± 0.6   20.3 ± 0.8   22.5 ± 1.2   0.305   20.6 ± 0.7   19.9 ± 0.9   22.1 ± 1.3   0.166   22.3 ± 1.5   21.5 ± 1.8   24.1 ± 3.1   0.460
   HRQL                    42.6 ± 1.2   40.9 ± 1.5   46.4 ± 2.0   0.036   43.0 ± 1.3   41.2 ± 1.6   46.5 ± 2.3   0.059   41.5 ± 3.0   39.7 ± 3.8   45.6 ± 4.6   0.387
  OABSS                    9.0 ± 0.2    8.9 ± 0.3    9.5 ± 0.6    0.325   9.1 ± 0.3    8.7 ± 0.4    9.9 ± 0.6    0.103   8.9 ± 0.5    9.4 ± 0.7    7.8 ± 0.6    0.203
  Urinary NGF/Cr (pg/mg)   1.1 ± 0.2    1.2 ± 0.3    1.0 ± 0.4    0.572   1.3 ± 0.2    1.4 ± 0.3    1.0 ± 0.4    0.532   0.4 ± 0.1    0.7 ± 0.3    0.3 ± 0.1    0.083

Values are presented as mean±standard deviation or number (%).

BMI, body mass index; OAB, overactive bladder; OABq-SF, overactive bladder questionnaire short form; HRQL, health-related quality of life; OABSS, overactive bladder symptom score; NGF, nerve growth factor; Cr, creatinine.

Comparison between responders and nonresponders.

###### 

Logistic regression analysis with pre-treatment variables to predict response to antimuscarinic treatment

  Variable                  Overall            Female   Male                                                                                                                             
  ------------------------- ------------------ -------- ------------------ ------- ------------------ ------- ------------------ ------- ------------------- ------- ------------------- -------
  Age                       1.00 (0.97-1.03)   0.917                               1.04 (0.99-1.08)   0.065   1.05 (1.00-1.10)   0.070   0.89 (0.80-1.00)    0.059   0.90 (0.81-1.01)    0.077
  Sex                                                                                                                                                                                    
   Male                     Reference                                                                                                                                                    
   Female                   1.16 (0.39-3.41)   0.779                                                                                                                                     
  BMI (kg/m^2^)             0.87 (0.73-1.03)   0.111    0.88 (0.74-1.04)   0.141   0.84 (0.70-1.02)   0.081   0.80 (0.65-0.99)   0.085   1.00 (0.64-1.58)    0.973                       
  OAB subgroup                                                                                                                                                                           
   OAB-dry                  Reference                                              Reference                                             Reference                                       
   OAB-wet                  0.97 (0.38-2.45)   0.959                               1.57 (0.56-4.33)   0.383                              0.26 (0.02-2.92)    0.279                       
  OAB pathogenesis                                                                                                                                                                       
   Idiopathic               Reference                                              Reference                                             Reference                                       
   Neurogenic               0.75 (0.18-3.05)   0.688                               1.22 (0.26-5.63)   0.791                              0.73 (0.06-8.91)    0.808                       
  Micturitions/24 hr        1.06 (0.94-1.19)   0.302                               1.06 (0.93-1.22)   0.331                              1.05 (0.82-1.33)    0.693                       
  Urgency episo des/24 hr   1.08 (0.98-1.18)   0.089    1.07 (0.97-1.17)   0.143   1.09 (0.97-1.22)   0.135   1.04 (0.92-1.18)   0.169   1.07 (0.93-1.23)    0.320                       
  Urinary NGF/Cr (pg/mg)    0.96 (0.77-1.19)   0.722                               0.92 (0.73-1.17)   0.530                              5.54 (0.57-53.66)   0.139   5.31 (0.23-72.15)   0.196

OR, odds ratio; CI, confidence interval; BMI, body mass index; OAB, overactive bladder; NGF, nerve growth factor; Cr, creatinine.

###### 

Baseline characteristics of the no recurrence group and the recurrence group in patients who responded to medical treatment with antimuscarinics

  Variable                 Overall     Female      Male                                                                                                
  ------------------------ ----------- ----------- ----------- ------- ----------- ----------- ----------- ------- ----------- ----------- ----------- -------
  Age (yr)                 54.9 ±1.6   54.2 ±2.5   55.5 ±2.1   0.709   55.4±1.6    54.5 ±2.5   56.2 ±2.2   0.591   50.2 ±4.6   53.5±3.1    48.2 ±3.7   0.27
  Sex                                                          0.739                                                                                   
   Male                    14 (22.6)   6 (20.7)    8 (24.2)                                                                                            
   Female                  48 (77.4)   23 (79.3)   25 (75.8)                                                                                           
  BMI (kg/m^2^)            23.6±0.7    23.4 ±0.4   23.9 ±0.5   0.727   23.9 ±0.4   23.6 ±0.4   24.1 ±0.6   0.533   22.7 ±0.5   22.5 ±0.7   22.9 ±0.7   0.71
  OAB subgroup                                                 0.658                                       0.907                                       0.533
   OAB-dry                 41 (66.1)   20 (69.0)   21 (63.6)           33 (68.8)   16 (69.6)   17 (68.0)           8 (57.1)    4 (66.7)    4 (50.0)    
   OAB-wet                 21 (33.9)   9 (31.0)    12 (36.4)           15 (31.2)   7 (30.4)    8 (32.0)            6 (42.9)    2 (33.3)    4 (50.0)    
  OAB pathogenesis                                             0.186                                       0.187                                       0.707
   Idiopathic              54 (87.1)   27 (93.1)   27 (81.8)           43 (89.6)   22 (95.7)   21 (84.0)           11 (78.6)   5 (83.3)    6 (75.0)    
   Neurogenic              8 (12.9)    2 (6.9)     6 (18.2)            5 (10.4)    1 (4.3)     4 (8.3)             3 (21.4)    1 (16.7)    2 (25.0)    
  Micturitions/ 24 hr      11.7±0.4    12.3 ±0.7   11.2 ±0.5   0.209   11.6±0.5    12.0 ±0.8   11.2 ±0.5   0.891   12.0 ±0.8   13.2 ±1.0   11.1 ±1.1   0.225
  Urgency episodes/24 hr   7.7 ±0.5    8.1 ±0.9    7.5 ±0.5    0.843   7.5 ±0.6    7.8 ±1.0    7.2 ±0.6    0.634   8.7±0.9     9.2 ±2.0    8.4 ±0.6    0.728
  OAB-qSF                                                                                                                                              
   Symptom bother          20.3 ±0.8   19.9±1.1    20.6±1.2    0.675   19.9 ±0.9   20.3 ±1.2   19.4± 1.2   0.596   21.5 ±1.8   18.0 ±2.2   241 ±2.5    0.107
   HRQL                    40.9 ±1.5   39.5 ±1.7   42.1 ±2.4   0.386   41.2 ±1.6   41.4±1.8    41.0 ±2.5   0.882   39.7 ±3.8   32.0 ±2.3   45.6 ±5.7   0.077
  OABSS                    8.9 ±0.3    8.8 ±0.5    9.0 ±0.5    0.763   8.7 ±0.4    8.7±0.6     8.7±0.5     0.976   9.4 ±0.7    9.0 ±0.9    9.7±1.1     0.631
  Urinary NGF/Cr (pg/mg)   1.2 ±0.3    1.8 ±0.6    0.6±0.1     0.047   1.4±0.3     2.3 ±0.6    0.7 ±0.2    0.038   0.7±0.3     1.0 ±0.2    0.3±0.1     0.037

Values are presented as mean±standard deviation or number (%).

BMI, body mass index; OAB, overactive bladder; OAB-q SF, overactive bladder questionnaire short form; HRQL, health-related quality of life; OABSS, overactive bladder symptom score; NGF, nerve growth factor; Cr, creatinine.

Comparison between the no recurrence group and the recurrence group.

###### 

Logistic regression analysis to predict recurrence in the patients who responded to medical treatment with antimuscarinic

  Variable                                                                             Overall             Female   Male                                                                                                                             
  ------------------------------------------------------------------------------------ ------------------- -------- ------------------ ------- ------------------- ------- ------------------ ------- ------------------- ------- ------------------ -------
  Age                                                                                  1.01 (0.96-1.04)    0.704                               1.01 (0.96-1.06)    0.582                              0.99 (0.93-1.06)    0.967                      
  Sex                                                                                                                                                                                                                                                
   Male                                                                                Reference                                                                                                                                                     
   Female                                                                              0.81 (0.24-2.70)    0.739                                                                                                                                     
  BMI (kg/m^2^)                                                                        1.07 (0.88-1.30)    0.489                               1.07 (0.86-1.32)    0.524                              1.12 (0.64-1.97)    0.684                      
  OAB subgroup                                                                                                                                                                                                                                       
   OAB-dry                                                                             Reference                                               Reference                                              Reference                                      
   OAB-wet                                                                             1.27 (0.44-3.66)    0.658                               1.07 (0.31-3.65)    0.907                              2.00 (0.22-17.89)   0.535                      
  OAB pathogenesis                                                                                                                                                                                                                                   
   Idiopathic                                                                          Reference                                               Reference                                              Reference                                      
   Neurogenic                                                                          3.00 (0.55-16.20)   0.202                               4.19 (0.43-40.61)   0.216                              1.66 (0.11-24.25)   0.708                      
  Micturitions/24 hr                                                                   0.89 (0.75-1.05)    0.173    0.91 (0.75-1.10)   0.339   0.91 (0.76-1.09)    0.193   0.93 (0.76-1.13)   0.488   0.77 (0.51-1.16)    0.192   0.80 (0.53-1.22)   0.415
  Urgency episodes/24 hr                                                               0.96 (0.84-1.09)    0.567                               0.96 (0.84-1.11)    0.626                              0.92 (0.67-1.28)    0.658                      
  Change of urinary NGF/Cr (pg/mg)^[\*](#tfn3-inj-1732794-397){ref-type="table-fn"}^   2.05 (1.07-3.93)    0.029    2.43 (1.14-5.16)   0.020   2.10 (1.02-4.30)    0.042   2.02 (1.19-4.13)   0.043   1.95 (1.40-9.50)    0.040   1.78 (1.29-9.67)   0.042

OR, odds ratio; CI, confidence interval; BMI, body mass index; OAB, overactive bladder; NGF, nerve growth factor; Cr, creatinine.

Subtraction of urinary level of NGF/Cr at the end of treatment from urinary level of NGF/Cr at baseline.
